TipRanks
Advertisement
Advertisement

DE:6MK Stock Latest News

Shattuck Labs price target raised to $14 from $11 at Wedbush
The FlyShattuck Labs price target raised to $14 from $11 at Wedbush
2d ago
MRK
STTK
Merck: Emerging Immunology Strength and HS Execution Support Unchanged $160 Price Target and Buy Rating
PremiumRatings
Merck: Emerging Immunology Strength and HS Execution Support Unchanged $160 Price Target and Buy Rating
3d ago
MRK
Spyre Therapeutics price target raised to $130 from $121 at Jones
PremiumThe Fly
Spyre Therapeutics price target raised to $130 from $121 at Jones
3d ago
MRK
SYRE
Merck Buy Rating Reiterated as Compelling Tulisokibart Data and Diversified Pipeline Support Outlook; $170 Price Target Maintained
PremiumRatings
Merck Buy Rating Reiterated as Compelling Tulisokibart Data and Diversified Pipeline Support Outlook; $170 Price Target Maintained
3d ago
MRK
Shattuck Labs has positive readthrough from Merck data, says H.C. Wainwright
PremiumThe Fly
Shattuck Labs has positive readthrough from Merck data, says H.C. Wainwright
4d ago
MRK
STTK
Merck says tulisokibart met primary, secondary endpoints in Phase 2b study
PremiumThe FlyMerck says tulisokibart met primary, secondary endpoints in Phase 2b study
4d ago
MRK
Merck price target raised to $180 from $155 at Scotiabank
Premium
The Fly
Merck price target raised to $180 from $155 at Scotiabank
5d ago
MRK
Merck enters global license agreement with SciBrunch Therapeutics for SPR2015
Premium
The Fly
Merck enters global license agreement with SciBrunch Therapeutics for SPR2015
6d ago
MRK
Merck, Daiichi Sankyo voluntarily withdraw BLA for ifinatamab deruxtecan
PremiumThe Fly
Merck, Daiichi Sankyo voluntarily withdraw BLA for ifinatamab deruxtecan
8d ago
MRK
Merck, Eisai announce FDA approval of Welireg plus Lenvima
PremiumThe Fly
Merck, Eisai announce FDA approval of Welireg plus Lenvima
9d ago
MRK
FDA approves Welireg and Lenvima combo for ccRCC
PremiumThe Fly
FDA approves Welireg and Lenvima combo for ccRCC
9d ago
MRK
Merck’s remigromig meets primary endpoint in Phase 2b/3 DME trial
PremiumThe Fly
Merck’s remigromig meets primary endpoint in Phase 2b/3 DME trial
10d ago
MRK
Merck: Catalyst-Rich Oncology and Immunology Pipeline Supports Buy Rating; $166 Price Target Reaffirmed
PremiumRatingsMerck: Catalyst-Rich Oncology and Immunology Pipeline Supports Buy Rating; $166 Price Target Reaffirmed
11d ago
MRK
Merck says FDA approves update for U.S. product label for Winrevair
Premium
The Fly
Merck says FDA approves update for U.S. product label for Winrevair
12d ago
MRK
Trump Trade: U.S. announces deal with Denmark over Greenland’s security
Premium
The Fly
Trump Trade: U.S. announces deal with Denmark over Greenland’s security
13d ago
AZN
BMY
Merck says Japan’s MHLW approves Keytruda Qlex
PremiumThe Fly
Merck says Japan’s MHLW approves Keytruda Qlex
13d ago
MRK
U.S. weighs allowing most pharma licensing deals with China, Reuters says
PremiumThe Fly
U.S. weighs allowing most pharma licensing deals with China, Reuters says
16d ago
AZN
BMY
Merck says CHMP adopts positive opinion on Keytruda/Padcev combination
PremiumThe Fly
Merck says CHMP adopts positive opinion on Keytruda/Padcev combination
16d ago
MRK
Perspective Therapeutics announces trial collaboration agreement with Merck
PremiumThe Fly
Perspective Therapeutics announces trial collaboration agreement with Merck
20d ago
MRK
CATX
Merck price target raised to $172 from $150 at HSBC
PremiumThe FlyMerck price target raised to $172 from $150 at HSBC
24d ago
MRK
Leerink ups Merck price target on pipeline momentum
Premium
The Fly
Leerink ups Merck price target on pipeline momentum
25d ago
MRK
Merck price target raised to $161 from $127 at Leerink
Premium
The Fly
Merck price target raised to $161 from $127 at Leerink
25d ago
MRK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >